93 related articles for article (PubMed ID: 25605021)
1. TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer.
Nie W; Huang W; Zhang W; Xu J; Song W; Wang Y; Zhu A; Luo J; Huang G; Wang Y; Guan X
Oncotarget; 2015 Feb; 6(5):3003-12. PubMed ID: 25605021
[TBL] [Abstract][Full Text] [Related]
2. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
3. [Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway].
Lin YJ; Huang YH; Zhen YZ; Liu XJ; Zhen YS
Yao Xue Xue Bao; 2008 Nov; 43(11):1099-105. PubMed ID: 19239027
[TBL] [Abstract][Full Text] [Related]
4. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
[TBL] [Abstract][Full Text] [Related]
7. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Thoennissen NH; O'Kelly J; Lu D; Iwanski GB; La DT; Abbassi S; Leiter A; Karlan B; Mehta R; Koeffler HP
Oncogene; 2010 Jan; 29(2):285-96. PubMed ID: 19855437
[TBL] [Abstract][Full Text] [Related]
8. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
9. Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1.
Yamaguchi F; Takata M; Kamitori K; Nonaka M; Dong Y; Sui L; Tokuda M
Int J Oncol; 2008 Feb; 32(2):377-85. PubMed ID: 18202760
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.
Park JW; Lee SH; Woo GH; Kwon HJ; Kim DY
Biochem Biophys Res Commun; 2018 Apr; 498(3):566-572. PubMed ID: 29524408
[TBL] [Abstract][Full Text] [Related]
11. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
13. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
Katdare M; Osborne M; Telang NT
Int J Oncol; 2002 Oct; 21(4):809-15. PubMed ID: 12239620
[TBL] [Abstract][Full Text] [Related]
14. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
15. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin.
Sun SH; Huang HC; Huang C; Lin JK
Eur J Pharmacol; 2012 Sep; 690(1-3):22-30. PubMed ID: 22705896
[TBL] [Abstract][Full Text] [Related]
16. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
18. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]